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Science (from the Latin scientia, meaning 
"knowledge") is an enterprise that builds and 
organizes knowledge in the form of testable 
explanations and predictions about the natural 
world. 
 
Science is proud to make predictions with 
great probability, bearing in mind that the 
most likely event is not always what actually 
happens. 
 
  
 
 
  
ABSTRACT 
 
Streptococcus pneumoniae (the pneumococcus) most commonly colonizes the human 
nasopharyngeal mucosa without causing any symptoms. However, this organism has 
the potential to spread to normally sterile sites and cause pneumonia, meningitis or 
sepsis; diseases which are characterized by excessive inflammation. Despite the large 
burden of pneumococcal disease, relatively little is known about the mechanisms 
behind development of natural immunity to the pneumococcus. The purpose of this 
thesis was to study the role of human dendritic cells (DCs) in linking innate and 
adaptive immune responses to pneumococci. The immunological events in which DC-
mediated T helper (Th) cell responses are generated were also investigated, as well as 
possible ways to modulate these responses. 
As a first part of this work, a novel role of the pneumococcal toxin 
pneumolysin in the evasion of DC-mediated immunosurveillance was described. 
Pneumolysin inhibited DC maturation, production of inflammatory cytokines and 
inflammasome activation, and induced caspase-dependent apoptosis of infected cells. 
Interestingly, murine DCs differed in their response to pneumolysin, emphasizing the 
need to study human responses to this human-specific pathogen. 
In the second part of this work, we demonstrated that pneumococcus-
infected monocytes and DCs efficiently promote the production of inflammatory Th1 
and Th17 cytokines from autologous co-cultured memory cells. Live pneumococci and 
pneumococcal peptidoglycan triggered activation of DCs, which in turn induced the 
generation of Th cytokines via cell-to-cell contact and soluble components. Our work 
further revealed that the inflammatory response could be modulated with exogenous 
substances, such as recombinant cytokines, and cytokine- and receptor-blocking 
antibodies. Moreover, exposure of DCs to vitamin D skewed the response from an 
inflammatory Th1/Th17 phenotype towards a regulatory T cell phenotype. 
 In the last part of this work, we focused on patients with primary 
immunodeficiencies (PIDs), suffering from frequent respiratory tract infections. The 
mechanisms behind the infectious susceptibility among these patients remain elusive 
and we hypothesized that it may be due to defects in the production of antimicrobial 
peptides (AMPs) in the nasal mucosa. We found that two patient groups, namely 
common variable immunodeficiency (CVID) and Hyper-IgE syndrome (HIES), had a 
dysregulated AMP response to bacteria in the upper respiratory tract. In addition, 
cells from these patients exhibited an impaired Th17 cytokine response. 
 In order to improve management of patients with pneumococcal 
infections there is a need to elucidate the role of DC-mediated cytokine responses in the 
delicate balance between protective immunity and immunopathology. An increased 
understanding of these processes is also essential for the development of pneumococcal 
vaccines, designed to elicit cell-mediated immunity. The work presented in this thesis 
contributes to our understanding of the dynamic interplay between pneumococci and 
host cells, and provides the opportunity to explore the potential role of vitamin D in 
limiting the inflammatory response in pneumococcal disease. 
  
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Uppskattningsvis dör årligen en miljon barn under fem års ålder av sjukdomar 
orsakade av bakterien Streptococcus pneumoniae, eller pneumokocker som de kallas 
i dagligt tal. Sedan några år tillbaka vaccineras barn mot pneumokocker inom 
barnvaccinationsprogrammet. De vaccin som finns idag skyddar dock endast mot en 
bråkdel av de olika varianter av pneumokocker som cirkulerar. Dessutom har fattiga 
länder, där flest barn dör, begränsad tillgång till pneumokockvaccin i dagsläget.  
Pneumokocker finns emellertid periodvis i näsan hos en stor andel barn i 
världen utan att barnen blir sjuka, vilket kan tyckas paradoxalt. I dessa fall är barnen 
bärare av pneumokocker. Det är först när pneumokockerna sprider sig från de övre 
luftvägarna till andra delar av kroppen som de orsakar sjukdom, t.ex. 
öroninflammation som är en vanlig sjukdom hos barn. Ett mindre antal barn drabbas 
av mer allvarliga sjukdomar, såsom lunginflammation, hjärnhinneinflammation eller 
blodförgiftning. Dessa sjukdomar förekommer hos människor i alla åldrar, men det är 
främst de yngsta och äldsta individerna som är utsatta.  
Hur kommer det sig att en och samma bakterie kan å ena sidan leva i 
symbios med människan och å andra sidan orsaka allvarliga sjukdomar? Man kan 
tänka sig att både immunförsvaret hos den infekterade personen och faktorer hos 
bakterierna spelar en roll. Min forskning har syftat till att skapa en bättre förståelse för 
samspelet mellan pneumokocker och det mänskliga immunförsvaret för att möjliggöra 
utvecklingen av nya typer av vaccin och behandlingsstrategier. 
Det finns celler som är specialiserade på att aktivera och dirigera 
immunförsvaret så att sjukdomsalstrande bakterier snabbt kan upptäckas och 
elimineras. De kallas dendritiska celler. En detaljerad förståelse för vad som händer 
när dendritiska celler möter pneumokocker saknas och jag har därför studerat olika 
aspekter av samspelet mellan denna celltyp och pneumokocker. I min forskning har jag 
kunnat visa att flera viktiga funktioner hos de dendritiska cellerna slås ut av 
pneumokocker. Denna bakterie producerar nämligen ett gift, pneumolysin, som gör att 
de dendritiska cellernas förmåga att kommunicera med andra celler i immunförsvaret 
försvagas. Detta kan vara ett sätt för pneumokockerna att undvika att bli upptäckta av 
immunförsvaret. 
Man vet att andelen bärare är lägre bland äldre barn, och hos vuxna är 
andelen bärare mycket låg. Vad har immunförsvaret för roll i denna process? Har äldre 
barn och vuxna bättre motståndskraft mot pneumokocker? Forskare har studerat hur 
sådan motståndskraft skulle kunna uppstå och det har visat sig att T-hjälparceller är 
viktiga i sammanhanget. Av denna anledning har jag studerat hur dendritiska celler 
dirigerar T-hjälparceller i försvaret mot pneumokocker. Jag har kunnat visa att 
peptidoglykan, som är en del av pneumokockens cellvägg, aktiverar de dendritiska 
cellerna. Detta leder i sin tur till att T-hjälparcellerna startar en inflammation, vilket är 
det symtom som dominerar hos patienter med pneumokocksjukdomar. 
 Nyligen har forskare upptäckt att D-vitamin är viktigt för vårt 
immunförsvar och jag har därför också velat undersöka hur dendritiska celler påverkas 
av D-vitamin. Mina resultat tyder på att tillsats av D-vitamin dämpar den 
inflammatoriska process som pneumokockerna triggar. Eftersom 
pneumokockinfektioner ofta leder till en okontrollerad inflammation som skadar 
kroppens vävnader så kan man tänka sig att D-vitamin skulle kunna ha terapeutisk 
potential. Mer forskning inom ämnet är emellertid nödvändig för att tydligare förstå 
dessa mekanismer. 
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PREFACE 
 
Streptococcus pneumoniae (the pneumococcus) is one of the foremost bacterial 
pathogens in humans. Paradoxically, it is essentially a commensal organism that 
asymptomatically colonizes the nasopharynx of a significant proportion of the human 
population. Hence, a key question is why the majority of colonized individuals do not 
develop disease. Part of the answer lies in the dynamic interplay between pneumococci 
and cells of our immune system. To study the complex interactions between bacteria 
and immune cells has been an intriguing challenge, and my hope is that the work 
presented in this thesis provides insights into human immunity to the pneumococcus 
that can be used to identify possible points of intervention for treatment or 
vaccination. 
 1 
 
1 INTRODUCTION 
 
1.1 STREPTOCOCCUS PNEUMONIAE 
 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive encapsulated 
bacterium that was independently isolated and described by Louis Pasteur and George 
Sternberg in 1881 [2, 3]. It is a facultative anaerobe that can be grown on blood agar 
plates where it forms macroscopic colonies, and in the laboratory it can be identified 
by its α-hemolytic activity and optochin sensitivity. A thick polysaccharide capsule 
surrounds the pneumococcus (Figure 1), and based on differences in the composition 
of this capsule, more than 90 pneumococcal serotypes can be distinguished.  
 
 
 
 
 
The pneumococcal genome is a closed, circular DNA structure that contains 
approximately 2 million base pairs. Analysis of an increasing number of whole 
genome sequences has revealed that the pneumococcus is a genetically diverse 
bacterium. In fact, the genetic information can vary up to 10% between strains, and this 
is due to the fact that the pneumococcus is naturally transformable, i.e. it takes up 
DNA from the surroundings. This phenomenon was discovered by Frederick Griffith 
in 1928. He demonstrated that an unencapsulated avirulent pneumococcal strain could 
become encapsulated and virulent after the addition of a “transforming factor” from a 
heat-killed encapsulated strain [4]. In 1944, a time when it was widely believed that 
protein was the hereditary material of bacteria, Theodor Avery and colleagues made 
the groundbreaking discovery that the “transforming factor” in Griffith’s experiment 
was DNA [5]. 
 
 
1.1.1 The Pneumococcus – A Commensal or Pathogen? 
 
The pneumococcus is a human-specific bacterium. Hence, it has no animal reservoir 
and is not present in the environment. Instead, the main ecological niche for 
pneumococci is the human nasopharynx, where it forms part of the normal flora. 
Figure 1. Streptococcus pneumoniae. In the microscope, pneumococci 
appear as oval-shaped single cells, diplococci or chains. © M. Olliver 
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Asymptomatic nasopharyngeal carriage is most prevalent in young children, whereas 
adults are seldom carriers. When nasopharyngeal cultures for 1300 adults and 404 
children were analyzed, S. pneumoniae was carried by 53% of children (≤ 6 years), 
compared with 4% of the adults in the same community [6]. In children attending day 
care centers, up to 60% harbor the pneumococcus in the nasopharynx [7, 8]. 
 
Although transient nasopharyngeal colonization rather than disease is the normal 
outcome of exposure to S. pneumoniae, it is nevertheless a major human pathogen, 
causing substantial morbidity and mortality worldwide. Disease occurs when bacteria 
are inhaled into the alveoli, enter the bloodstream, or cross the blood-brain barrier, 
causing pneumonia, sepsis or meningitis. This versatile bacterium can also cause more 
benign conditions such as otitis media and sinusitis.  
 
Certain individuals have an increased risk of acquiring pneumococcal infections. Age, 
genetic background, socioeconomic status, immune status, geographic location and 
underlying disease are among the factors that determine the incidence of 
pneumococcal disease (Table 1). 
 
Table 1. Examples of risk factors for pneumococcal disease. 
Risk factor Examples 
Underlying disease Heart, kidney, liver or lung disease, cancer, diabetes [9, 10] 
Extremes of age <2 years or ≥65 years 
Primary 
immunodeficiency 
Sickle cell disease, common variable immunodeficiency, 
agammaglobulinemia, Hyper-IgE syndrome [11-14] 
Acquired 
immunodeficiency 
Organ transplant recipients, HIV infection [15] 
Crowding Schools, day care centers, jails, hospitals, military camps 
[16, 17]  
Ethnicity Indigenous peoples of Alaska, Australian aborigines, and 
New Zealand Maoris [18-20] 
Living in a 
developing country 
Poverty, malnutrition, poor access to medical care [1] 
Previous infection Influenza virus [21, 22] 
Other Alcohol and drug abuse, exposure to cigarette smoke [23] 
 
So is the pneumococcus a commensal or a pathogen? This question does not have a 
simple answer. Episodes of nasopharyngeal colonization usually do not lead to 
disease; hence, the pneumococcus is considered a commensal organism. When the 
host is in equilibrium with its commensal population of pneumococci, the bacteria are 
asymptomatically carried in the nasopharynx, which helps them persist in the human 
population. Here they can pass unnoticed while they live and feed on their host. 
However, in certain cases, host immune mechanisms are insufficient or dysregulated, 
rendering the host more susceptible to pneumococcal disease. This kind of imbalance 
may lead to immune-mediated pathology, since the pneumococcus is capable of 
triggering a highly inflammatory response that can become independent of bacterial 
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presence and lead to multiple organ failure and death. Thus, if this fine balance is 
broken, the pneumococcus has the potential to become a pathogen. 
 
 
1.1.2 Global Burden of Pneumococcal Disease 
 
Data on the global burden of pneumococcal disease are still limited; however, it has 
been estimated that pneumococcal disease annually cause about 826,000 deaths in 
children under the age of five [1] Even this is probably an underestimate since 
surveillance in high-mortality developing countries usually under-detects bacterial 
meningitis and sepsis incidence due to the low sensitivity of diagnostic tests and the 
limited access to care. The highest mortality rates are found in sub-Saharan Africa and 
south Asia (Figure 2), where ten countries account for 61% of all pneumococcal deaths 
[1]. 
 
 
 
 
 
Population-based data on invasive pneumococcal disease (IPD) in developed countries 
suggest an annual incidence of at least 15-20 cases per 100,000 persons of all ages and 
at least 50 cases per 100,000 elderly adults (≥65 years) [24]. These estimates 
correspond with Swedish statistics from 2011, where the incidence of IPD was 14 cases 
per 100,000 persons of all ages, with 66% of cases in adults older than 60 years [25]. 
 
Pneumococcal serotypes differ in carriage prevalence and disease incidence [26], and 
the spectrum of prevailing capsular types varies with age, time and geographical 
region. There have been numerous epidemiological studies to investigate which 
serotypes are the most prevalent causes of disease in certain geographical regions at 
certain time points. These types of studies show that the majority of the burden of 
pneumococcal disease is associated with a rather restricted number of serotypes [27]. 
Figure 2. Pneumococcal mortality rate. Pneumococcal deaths in children aged < 5 years per 
100 000 (HIV-negative pneumococcal deaths only). Adapted from [1]. 
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Moreover, it appears that some serotypes mainly affect younger children while others 
mainly affect the elderly [28]. Furthermore, some serotypes mainly infect previously 
healthy individuals whereas others primarily affect patients with underlying disease 
[28], suggesting that some pneumococcal isolates behave as primary pathogens 
whereas others are more opportunistic. 
 
 
1.1.3 Prevention and Treatment of Pneumococcal Infections 
 
The fight against pneumococcal disease has achieved significant results in the last 
decades, but the challenge is still ongoing. The main strategy to prevent 
pneumococcal infections is through vaccination, and the development of effective and 
affordable vaccines has been a global health priority for many decades. However, 
there are several challenges for vaccine development, as will be discussed here. 
 
 
Prevention 
 
Two vaccine formulations are available to prevent pneumococcal infection: the 
polysaccharide vaccine and the conjugate vaccine. The polysaccharide vaccine is 
based on capsule components of the 23 most common capsular serotypes that cause 
severe pneumococcal disease in the developed world. This type of vaccine has been 
in use since the 1970s [29] and is recommended for individuals older than 65 years, 
as well as other groups with an increased risk of pneumococcal disease. 
 
Antibodies to the capsular polysaccharide antigens provide serotype-specific 
protection against pneumococcal infections. However, this vaccine induces a T-cell-
independent B cell response, and therefore its effectiveness is hampered by poor 
responses in children younger than 2 years of age who have inadequate production of 
antibodies to polysaccharide antigens. For this reason, polysaccharide vaccines fail to 
protect infants and small children [30]. There is also skepticism about the 
effectiveness and efficacy of this vaccine against pneumonia in the elderly and in 
immunocompromised adults [31].  
 
Since young children and the elderly are precisely the risk groups for severe 
pneumococcal disease, several vaccine manufacturers have in the last 15 years 
developed new vaccines, in which a number of capsular polysaccharides are covalently 
coupled to a protein carrier, called conjugate vaccines. These vaccines are highly 
immunogenic in all age groups and induce a T-cell dependent immune response 
characterized by immune memory. Importantly, they stimulate mucosal immunity, 
which reduces nasopharyngeal carriage. Lower carriage rates among vaccinated 
children, who are thought to be the most important vector for horizontal 
dissemination of pneumococci [32], reduces transmission of vaccine-type 
pneumococci in the community, hence, conferring herd immunity among unvaccinated 
adults [33, 34]. 
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A 7-valent conjugated pneumococcal vaccine was approved by the United States 
Food and Drug Administration (FDA) in 2000. This vaccine contains polysaccharides 
of the most seven common serotypes known at the time to cause IPD in the United 
States. 10- and 13-valent conjugate vaccines have now been introduced into routine 
infant immunization programs of several countries, including Sweden. 
 
Use of the conjugate vaccine has modified the epidemiology of IPD in the population 
and led to a significant decrease in IPD with included serotypes [33, 35, 36]. Between 
1999 and 2003 in the United States, the effectiveness of the 7-valent conjugate 
vaccine against IPD caused by vaccine serotypes in children below 5 years of age 
declined from 80 to 4.6 cases per 100,000 inhabitants, meaning an overall 94% 
decline [37]. In South Africa, vaccine efficacy against vaccine serotypes was 83% 
[38]. Reduction in pneumococcal disease has also been observed among unvaccinated 
age groups [39, 40], demonstrating that the conjugate vaccine provides herd immunity. 
However, despite the effectiveness of this vaccine, there may be a limited lifespan to 
the observed benefits, for the following reasons: 
 
Coverage is limited 
Although the conjugate vaccine has been shown to be effective against both invasive 
and non-invasive disease, the current licensed products contain a limited number of 
serotypes and cannot be expected to provide protection against carriage or disease 
caused by most other serotypes. In addition, coverage varies in different populations 
and may be lower in many developing countries. Furthermore, the prevalence of 
pneumococcal serotypes fluctuates over time and region [41], demonstrating the 
difficulty in choosing a limited number of capsular types to include in a 
polysaccharide-based vaccine 
 
Expensive vaccine that does not reach the right population 
An additional challenge in the prevention of IPD is for the vaccine to reach the right 
population. Despite the considerable burden of disease caused by pneumococci, the 
available conjugate vaccine has yet to be launched in the majority of low-income 
settings where it is most needed. Vaccination is urgently needed in Africa and Asia, 
which together account for 95% of all pneumococcal deaths [1]. One obvious limiting 
factor is the high price of the conjugate vaccine. Another factor is the cold chain, i.e. 
the vaccine requires a temperature of approximately 8 degrees Celsius, and thus 
transport and storage of the vaccine within the safe temperature range is essential. 
 
Emergence of non-vaccine serotypes 
In parallel with the dramatic decrease of IPD caused by vaccine serotypes, there has 
been an increased rate of IPD due to non-vaccine serotypes [42-44]. Evidence from 
several countries suggests that serotype replacement in carriage has emerged as a 
consequence of vaccination. Serotype 19A has become particularly important because 
an increased incidence of IPD caused by 19A has been shown in different populations 
[45, 46]. Mera et al. reported an increase in serotype 19A from 3% to 20% before and 
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after introduction of the vaccine [47]. Hence, continued surveillance of serotype 
distribution is essential to allow rational vaccine design. 
 
These important shortcomings underline the need for developing improved 
pneumococcal vaccines in order to provide protective immunity against a larger 
number of serotypes. New vaccine strategies focus on the use of highly conserved 
immunogenic surface-associated proteins (reviewed in [48]). This type of vaccine has 
several advantages as it is expected to elicit protection in all age group, induce broad 
and serotype-independent protection, and be cheap to produce. Many protein vaccine 
candidates are under investigation, however, at present, the search for a protein-based 
universal pneumococcal vaccine covering all serotypes remains in its infancy. 
 
Another possible approach, which has been evaluated by the group of Richard 
Malley, is a killed unencapsulated whole-cell vaccine, shown to be effective in 
preventing nasopharyngeal colonization with encapsulated pneumococci in mice [49]. 
This type of vaccine has properties that makes it suitable for use in developing 
countries, including coverage irrespective of serotype, low cost, stability following 
lyophilization (thus avoiding cold chain issues), and mucosal administration [50]. 
 
Although it may seem a good idea to completely eradicate pneumococci from the 
nasopharynx, there is an important caveat. Clearing the nasopharynx of this organism 
might lead to replacement with other species, providing opportunities for potential 
pathogens that normally compete with the pneumococcus for the nasopharyngeal niche. 
For this reason, perhaps one should hesitate before intervening with a bacterium that 
has been colonizing humans for a very long time. Also, acquisition of natural immunity 
to the pneumococcus might be more important than we realize, as multiple exposure 
events throughout life may maintain protection against pneumococcal disease. 
Ultimately, future pneumococcal vaccines should aim to mimic natural immunity with 
the objective to protect against disease rather than colonization. 
 
 
Treatment 
 
In the beginning of the 20
th
 century, pneumococcal pneumonia was treated with type-
specific antisera [51]. Controlled clinical trials conducted in the 1920s demonstrated 
the benefit of pneumococcal type-specific antiserum by comparing mortality among 
patients given antiserum treatment with that among control patients who received no 
specific therapy [52]. Rapid provision of serum to patients with pneumococcal 
pneumonia was a major public health initiative of the late 1930s. However, with the 
advent of antibiotics, the antiserum programs soon collapsed and pneumonia reverted 
to the domain of the private practitioner [53]. 
 
Penicillin, introduced in the 1940s, proved to be highly effective against pneumococci 
and has ever since been the most commonly used drug for pneumococcal infections.  
However, treatment of pneumococcal infections with β-lactam antibiotics, such as 
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penicillin, can result in the paradoxical enhancement of inflammation. This is due to 
the release of proinflammatory cell wall products [54], and it has been suggested that 
anti-inflammatory drugs should be administered concurrently with the antibiotics in 
patients with meningitis [55].  
 
As with many other bacteria, the use of antibiotics has led to the emergence and 
spread of resistant strains of pneumococci. Resistance to penicillin is related to 
structurally modified penicillin-binding proteins that allow peptidoglycan synthesis 
despite the presence of penicillin. Penicillin resistant strains were first noted in the 
mid 1970s and resistant clones have now spread worldwide [56-58]. When 
susceptibility testing was examined in eight European countries, an overall of 25% of 
isolates were nonsusceptible to penicillin [59]. However, the prevalence of penicillin 
resistance varies between European countries, and in Sweden, resistance to penicillin 
among invasive isolates has remained around 3% [60]. 
 
Antimicrobial resistance of pneumococci to fluoroquinolones, macrolides, 
vancomycin and other antibiotics is increasingly recognized worldwide [61, 62]. 
Therefore, prudent use of antimicrobial agents is needed, as well as discovery of new 
antimicrobial agents. The escalation of antimicrobial resistance among pneumococci 
emphasizes the importance of preventing pneumococcal disease through 
immunization and the urgent need for development of new vaccines.  
 
 
1.1.4 Disease Pathogenesis 
 
Pneumococci are transmitted from person to person by sneezing, coughing or through 
direct contact. Colonization of the nasopharynx, especially in young children, 
provides the major reservoir for transmission of pneumococci [63], and nasopharyngeal 
carriage is thought to be a prerequisite of disease. Through a combination of virulence 
factor activity, the pneumococcus is able to evade the host immune response and 
spread from the nasopharynx to the ear, sinus, lung, blood and meninges, causing a 
variety of diseases (Table 2). When pneumococci invade normally sterile sites, such 
as the bloodstream and meninges, the resulting forms of pneumococcal disease are 
classified as invasive. 
 
Table 2. Overview of diseases caused by pneumococci. 
 Disease Part of the 
body 
Symptoms 
Non-
invasive 
Otitis media Middle ear Pain in the ear and fever 
Sinusitis Paranasal 
sinuses 
Headache, pressure or pain in the sinuses, 
thick nasal discharge  
Pneumonia Lung Fever, productive cough, headache, 
shortness of breath, chest pains 
Invasive Sepsis Blood Fever, headache, muscular aches 
Meningitis Meninges Fever, headache, vomiting, neck stiffness 
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Otitis media 
 
Acute otitis media is the most common clinical manifestation of pneumococci and at 
the age of two years, most children have experienced at least one episode of 
pneumococcal otitis media [64]. The pneumococcus is the leading cause of otitis 
media, although it can also be caused by other bacterial pathogens, including 
Haemophilus influenzae and Moraxella catarrhalis. Major risk factors for developing 
otitis media is eustachian tube dysfunction (ineffective clearing of bacteria from the 
middle ear) and repeated exposure to large numbers of other children, whether at 
home or in day care [64].  
 
Very little is known about the process of which pneumococci gain access to the 
middle ear. The bacteria must first progress up the eustachian tube, and once in the 
middle ear, they trigger a cytokine response that results in the influx of neutrophils. 
Several animal studies have demonstrated that pneumococcal cell wall components 
play a major role in generating the inflammation that characterizes pneumococcal 
otitis media [65, 66]. Complications of otitis media include permanent hearing loss, 
mastoiditis (spread of the infection into the area of bone underneath the ear), facial 
paralysis and meningitis. Children with recurrent episodes of acute otitis media have a 
higher risk of developing hearing loss [67]. 
 
 
Sinusitis 
 
The pneumococcus is one of the most common etiological agents of sinusitis, which is 
characterized by inflammation of the lining of the paranasal sinuses. It can be 
precipitated by allergy or a viral upper respiratory tract infection. 
 
 
Pneumonia 
 
S. pneumoniae  is the most common cause of community-acquired pneumonia (CAP) 
[10]. In both Europe and the USA, CAP is the most frequent cause of death from 
infection [68]. Despite advances in diagnostic methods and intensive care support, 
mortality in pneumococcal pneumonia remains high, ranging from 7% to 36% [69, 
70] and may exceed 50% in groups with predisposing factors [71]. In 20-30 % of cases 
with pneumococcal pneumonia, bacteria spread to the blood and cause sepsis. 
Pneumonia can also lead to complications such as pleural empyema (the accumulation 
of pus in the pleural cavity). After the introduction of the 7-valent conjugate vaccine, 
increases in the incidence of empyema, associated with the emergence of nonvaccine 
serotype 1, have been reported [72]. 
 
Pneumonia arises when pneumococci reach the alveoli where they multiply and spread, 
causing cytokine production and influx of white blood cells to the alveoli. The resulting 
tissue destruction leads to lack of oxygen and cyanosis. Alveolar macrophages 
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represent the first phagocytic defense in the lungs [73], however, when a large number 
of pneumococci are introduced into the lower airways, neutrophils become the main 
phagocytic cells in response to pneumococcal pulmonary infection in mice [74]. 
Migration of neutrophils into the lung tissue can be both good and bad; Neutrophils are 
considered important effector cells in the host defense but they can also induce 
inflammation and tissue damage. Accordingly, it has been found that depletion of 
neutrophils can either result in increased mortality [75] or improved survival [76] in 
intranasally infected mice. These findings suggest that the role played by neutrophils in 
pneumococcal pneumonia requires closer scrutiny. Interestingly, peripheral neutropenia 
is generally not considered to be a risk factor for adult pneumococcal disease. 
Nevertheless, neutropenia is a poor prognostic finding in patients with established 
pneumococcal disease [77]. 
 
 
Sepsis  
 
When bacteria reach the bloodstream they can cause a systemic inflammation called 
sepsis, which, if not treated, can lead to multisystem organ failure and death. 
Pneumococcal sepsis is associated with a significant mortality rate, ranging from 13% 
to 36% [78-80] and at least 50% of mortality occurs within the first 48 hours of 
admission [78, 79]. 
 
The mechanisms by which pneumococci breach the epithelium and get access to the 
circulation are still not well understood. Bacterial cell wall fragments may stimulate the 
release of cytokines and chemokines, and mechanisms that normally control a local 
infection become detrimental during this systemic dissemination. From the blood, 
pneumococci may pass the blood-brain barrier and cause meningitis. 
 
 
Meningitis 
 
The most common etiological agents of community-acquired bacterial meningitis are S. 
pneumoniae and Neisseria meningitidis. Despite advances in medical care, mortality 
from pneumococcal meningitis ranges from 25-30% [81-83]. Neurological sequelae are 
common and include hearing loss, cognitive impairment, blindness, and paralysis. 
Neuronal damage in bacterial meningitis is caused by the dual effects of an 
overwhelming inflammatory reaction and direct effects of bacterial toxins [84]. 
Pneumococcal pneumolysin and hydrogen peroxide (H2O2) have been shown to 
mediate brain cell apoptosis in mice [85]. The same investigators showed that 
pneumolysin functions as a mitochondrial toxin and a determinant of caspase-
independent apoptosis, causing neuronal cell death [86]. 
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1.2 THE IMMUNE SYSTEM 
 
Our immune system is an extremely complex organization of multiple cell types and 
structures that together make up a defense system against microorganisms. The 
immune system can be divided into two categories: the innate and the adaptive host 
defense. The innate immune system rapidly recognizes bacterial, viral, fungal and 
parasitic elements that are conserved across organisms, whereas adaptive immune 
responses develop against specific epitopes contained within these organisms. 
However, it is important to note that the innate and adaptive immune systems work 
together in the clearance of microbes. 
 
 
1.2.1 Innate Immunity 
 
The innate immune system includes cells such as monocytes, macrophages, dendritic 
cells (DCs), mast cells, NK cells and neutrophils. There are also humoral components 
such as the complement system and antimicrobial peptides (AMPs). Additionally, 
innate immunity includes anatomical barriers such as the skin and epithelium, as well 
as secreted mucus. Innate host responses are critical to the outcome in bacterial 
infections and will be discussed here in relation to pneumococcal infections. 
 
 
Dendritic cells 
 
DCs are crucial cells of the innate immune system, with a superior ability to take up, 
process and present antigens compared with other antigen presenting cells (APCs). 
They are often described as the “conductors” of the immune response in their 
capacity to orchestrate signals derived from different parts of the immune system, 
serving as a link between innate and adaptive immunity [87]. DCs are particularly 
abundant at the major portals of microbial entry, including skin and mucosa [88], and in 
the lungs, they form a network of sentinel cells specialized in sampling inhaled bacterial 
pathogens [89, 90]. 
 
Ralph Steinman and Zanvil Cohn were the first to describe dendritic cells [91]. They 
identified this cell in the secondary lymphoid organs of mice using microscopy 
techniques. The most striking feature of the DC is its surface projections, which extend 
and retract from the cell body. In 2011, Ralph Steinman was awarded the Nobel Prize 
in Physiology or Medicine for his discovery of the DC and its role in adaptive 
immunity [92]. 
 
DCs can be categorized into multiple subsets. The two broadest categories are myeloid 
and plasmacytoid DCs. Myeloid DCs include epidermal and dermal DCs, which are 
found in peripheral tissues, as well as immature myeloid DCs that circulate in the 
blood. Myeloid DCs can also be generated in vitro from monocyte blood precursors. 
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Plasmacytoid DCs are found in blood as well as in peripheral lymphoid organs, and can 
produce large amounts of IFN-α and IFN-β upon stimulation. 
 
Maturation of DCs is a pivotal process for initiating immunity (Figure 3). On 
recognition of microbes, DCs undergo a process of maturation which is characterized 
by the upregulation of MHC, as well as costimulatory molecules CD80 and CD86 [93]. 
Maturation also results in the expression of cytokines and chemokines, and increased 
antigen processing and presentation. Mature DCs are able to prime naïve T cells by the 
release of cytokines that promote T helper (Th) 1, Th2, Th17 or regulatory T cells.  
 
 
 
 
 
 
One of the hallmarks of DC biology is their ability to migrate. Following antigen 
uptake in tissues, DCs migrate to the draining lymph nodes to stimulate T cell 
responses. Hence, expression of the lymphoid chemokine receptor CCR7 is also 
induced during DC maturation [94] 
 
To promote colonization or cause invasive disease pneumococci have to overcome DC-
based immunosurveillance in the upper respiratory tract. Cytokines and chemokines 
produced by the DCs at the site of pneumococcal entry will drive inflammatory signals 
which regulate resident and newly arrived phagocytes. DC-produced cytokines will 
also play a role in the effector functions of B and T cells. However, the mechanisms of 
recognition, uptake and intracellular fate of intact pneumococci by DCs have not been 
studied in great detail. One of the objectives with this thesis was thus to characterize 
DC responses to live pneumococci and identify bacterial factors involved in cellular 
activation. These kinds of experiments can provide basic information about the 
pathogenesis of pneumococcal infections, giving us further insight into the immune 
modulation induced by pneumococci, and improve the likelihood that we can 
manipulate these responses for our own interest. 
 
Figure 3. DC maturation. Immature DCs lose their phagocytic capacity and up-
regulate MHC class II, the co-stimulatory molecules CD80 and CD86, and the 
chemokine receptor CCR7. They also start producing cytokines and chemokines. © 
M. Olliver 
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Monocytes, Macrophages and Neutrophils 
 
Phagocytes are immune cells that can ingest (phagocytose) particles, such as bacteria, 
parasites and dead host cells. Besides DCs, the professional phagocytes of the human 
immune system include monocytes, macrophages and neutrophils. Phagocytes have 
many types of receptors on their surface that increase phagocytosis of bacteria which 
have been coated with antibodies or complement.  
Monocytes participate in innate immune responses through the effector and 
regulatory functions of monocyte-derived macrophages and DCs. Interestingly, 
Randolph et al. showed that monocytes are able to migrate from peripheral tissues 
into the T cell zone of draining lymph nodes upon stimulation [95]. Hence, activated 
monocytes may be involved in T cell differentiation in vivo. 
 
Macrophages are derived from blood monocytes and are present in virtually all tissue. 
Alveolar macrophages, a type of macrophage found in the pulmonary alveolus, are 
considered major effector cells in host defense against respiratory tract infections by 
virtue of their potent phagocytic properties. In murine models of pneumococcal 
pneumonia it has been shown that following exposure to pneumococci, alveolar 
macrophages rapidly transport bacteria from the lung to draining lymph nodes [96]. 
Alveolar macrophages also have a protective anti-inflammatory role, possibly by 
clearing apoptotic neutrophils [97]. 
 
Neutrophils are among the first immune cells recruited from the blood stream to the 
site of infection. They recognize bacteria via C3b complement receptor (CR3) or Ig 
Fc receptors and engulf them into vesicles called phagosomes. Bacteria are killed 
with non-oxidative (AMP-mediated) and oxidative mechanisms when the phagosome 
fuses with intracellular granules to form a phagolysosome. Neutrophils can form 
neutrophil extracellular traps (NETs), which are networks of extracellular fibers, 
composed of chromatin DNA, histones, enzymes and AMPs. NETs can kill microbes 
exracellularly by providing a high local concentration of antimicrobial components. 
Beiter et al. found that NETs are formed in the lungs of mice intranasally infected 
with pneumococci, and that pneumococci are captured but not killed by NETs in vitro 
[98]. Expression of the DNase EndA and the polysaccharide capsule, were identified 
as factors that helped pneumococci evade NETs [98]. 
 
 
Pattern Recognition Receptors 
 
The first recognition of bacteria by the host is mediated by pattern recognition receptors 
(PRRs). These receptors are activated by microbe-associated molecular patterns 
(MAMPs), bacterial virulence factors, as well as endogenous molecules released after 
tissue damage. Activated PRRs regulate the production of inflammatory cytokines that, 
in turn, stimulate neighboring immune and non-immune cells, starting an immune 
response.  
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Examples of PRRs are the Toll-like receptors (TLRs) and the NOD-like receptors 
(NRLs), which will be described here. A combination of signaling through TLRs and 
NLRs leads to the synergistic activation of immune responses, and a crosstalk between 
these receptors is probably crucial for the balance of the immune effector arms. 
 
Toll-like receptors 
TLRs are a family of host defense receptors that consists of 10 members in humans 
(Table 3) and 13 in mice. APCs have been the primary focus of TLR investigation; 
however, TLRs are also expressed on cells of the adaptive immune system [99] and 
non-immune cells, such as epithelial cells [100]. TLRs found in the epithelium of the 
respiratory tract may thus contribute to the immune response to airborne antigens 
such as S. pneumoniae. 
 
Table 3. TLRs and their ligands. 
Receptor Location Ligand 
TLR1/2 Cell surface Lipoproteins  
TLR2 Cell surface 
 
Lipoproteins, Lipoteichoic acid, 
Zymosan  
TLR2/6 Cell surface Di-acyl lipopeptides 
TLR3 Endosome Double-stranded viral RNA 
TLR4 Cell surface LPS from Gram negative bacteria 
Pneumolysin 
TLR5 Cell surface Bacterial flagellin 
TLR7 Endosome Single-stranded viral RNA 
TLR8 Endosome Single-stranded viral RNA 
TLR9 Endosome Bacterial CpG motifs 
TLR10 Cell surface Unknown 
 
Several TLRs have been shown to play important but partly redundant roles in the 
innate defense against pneumococci (reviewed in [101]). TLR2 has been investigated 
in different mouse models and is suggested to enhance pneumococcal phagocytosis 
and intracellular killing [102, 103], and protect the host during meningitis [104]. 
However, other investigators have established that TLR2 does not contribute to an 
effective antibacterial defense [105, 106], suggesting that other components of the 
immune system are sufficient to maintain an adequate response.  
 
TLR9 has been implicated as an important player in protective immunity in 
pneumococcal pneumonia. TLR9
-/-
 mice had reduced survival in a model of 
pneumonia, and macrophages deficient in TLR9 were shown to be impaired in 
pneumococcal uptake and killing [106].  
 
In addition to TLR2 and TLR9, TLR4 appears to play a role in pneumococcal 
infection by its sensing of pneumolysin [107]. However, it is possible that this is an 
indirect effect of TLR4 recognition of endogenous ligands released after bacteria-
induced host cell damage [108].  
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Nod-like receptors  
The family of NLRs consists of 22 mostly cytosolic proteins in humans and 33 
members in mice. Nucleotide-binding Oligomerization Domain (NOD) 1 and 2 are 
cytosolic receptors that have important roles in innate immunity as sensors of microbial 
components derived from bacterial peptidoglycan. NOD1 detects peptidoglycan 
fragments produced by Gram-negative bacteria, whereas NOD2 is activated by 
peptidoglycans of basically all bacteria [109]. Specifically, NOD2 is a sensor of 
peptidoglycan through the recognition of muramyl dipeptide (MDP), the minimal 
bioactive peptidoglycan motif common to all bacteria [110]. 
 
Opitz et al. showed that NOD2 activates the transcription factor NF-κB after 
detecting internalized pneumococci in vitro [111] and Davis et al. recently showed 
that macrophage phagocytosis and digestion of pneumococci leads to pneumolysin-
mediated delivery of peptidoglycan fragments into the host cell cytosol, triggering 
NOD2 activation [112]. 
 
 
Antimicrobial Peptides 
 
AMPs are components of the innate immune response that have a broad spectrum of 
antimicrobial activity against viruses, bacteria and fungi [113]. The initial contact 
between AMPs and bacteria is thought to be electrostatic since AMPs are positively 
charged and bacterial surfaces are negatively charged. The majority of AMPs kill 
bacteria by inserting themselves into the cell membrane bilayers, forming pores that 
disrupt cell membrane function.  
 
In humans, there are two main families of AMPs: defensins and cathelicidins [113]. 
The two main defensin subfamilies are α-defensins (produced by neutrophils and 
intestinal Paneth cells) and β-defensins (produced by epithelial cells of the lung, skin 
and gut). Defensins are abundantly represented in humans cells and tissues and 
because of their ability to kill a variety of microbes under laboratory conditions, they 
are thought to function as natural antibiotics [114]. 
 
Only one type of cathelicidin, called LL-37, is found in humans and is produced by 
neutrophils, mononuclear cells and epithelia. In addition to its antimicrobial effects, 
LL-37 has prominent chemotactic activities on neutrophils and T cells [115]. 
Interestingly, incubation of human DCs with LL-37 caused an increased activation of 
the DCs [116], suggesting that LL-37 released upon triggering of innate immunity 
may shape adaptive immune responses through an interaction with DCs. 
 
 
1.2.2 Adaptive Immunity 
 
The adaptive immune system is composed of highly specialized cells, including 
antibody-producing B cells and various kinds of Th cells and cytotoxic T cells. By 
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genetic recombination, B and T cells can generate a vast number of different antigen 
receptors, uniquely expressed on each individual cell. This process results in the 
generation of a diverse, yet specific, repertoire of immune effectors. 
 
 
B Cells 
 
The principal functions of B cells are to make antibodies, perform the role of APCs and 
develop into memory cells. Antibodies, also known as immunoglobulins (Igs), are large 
proteins that recognize and bind to antigens. There are five different classes of 
antibodies: IgG, IgM, IgA, IgE and IgD, which have different characteristics. 
 
B cell immunity appears to be necessary for protective immunity against 
pneumococci, as patients with B cell defects are prone to develop pneumococcal 
disease [13]. Patients with IgG2 subclass deficiency are for example more prone to 
develop sinusitis, pneumonia and IPD [117]. Little information is available on IgA 
deficiency and pneumococcal disease. IgA deficiency has a high incidence (1/800) 
but only 30% of patients with a complete lack of IgA in serum (<0.07 g/L) exhibit an 
increased susceptibility to infections. The reason for this observation is still unknown. 
In addition, IgA-deficient patients have a greater risk of developing autoimmune 
diseases, such as type 1 diabetes and thyroid disease, suggesting an underlying 
dysregulation of the immune system. Given the high prevalence of IgA-deficiency 
and the incomplete penetrance of the clinical phenotype, it is difficult to know if 
pneumococcal disease among these patients is caused by the immune defect per se or 
is a mere coincidence. 
 
 
T Cells 
 
T cells only recognize antigen when it is presented by an APC in the context of an 
MHC-peptide complex. There are two subset of T cells; CD8
+
 cytotoxic T cells and 
CD4
+
 Th cells.  
 
Naïve CD4
+
 T cells differentiate into effector cells when they encounter a foreign 
antigen presented by an APC in the context of environmental factors. The Th1 and Th2 
cell paradigm, which was first proposed by Mosmann and Coffman [118], has been 
used to explain how the host elicits different adaptive immune responses to eradicate 
various pathogens. Th1 effectors produce IFN-γ and regulate cellular immunity against 
intracellular infections, whereas Th2 cells produce IL-4, IL-5 and IL-13 and are 
important for humoral immunity and control of parasitic infections. 
 
The traditional paradigm of Th1/Th2 cell dichotomy changed when a third subset of Th 
effector cell was described: Th17 cells [119, 120]. Upon stimulation, Th17 cells 
acquire the capacity to produce the inflammatory cytokines IL-17, IL-21 and IL-22. 
The cytokines that instruct Th17 cell lineage development likely include IL-6, IL-1β, 
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IL-23 and IL-21 [121, 122]. Cytokine-driven activation of signal transducer and 
activator of transcription 3 (STAT3) pathway is an essential step in Th17 cell 
differentiation [123]. Th17 cells initially developed a reputation as a destructive 
element in animal models of autoimmune disease [124]. In humans, the reputation 
was due to correlative data documenting an increase in IL-17-producing cells at sites 
of tissue inflammation. Hueber et al. found that human neutralizing antibodies to IL-
17 are effective in both psoriasis and rheumatoid arthritis [125], indicating that Th17 
cells are likely to be harmful in these diseases. However, we now know that although 
Th17 cells participate in the pathogenesis of several autoimmune diseases, they can 
contribute to protection in other diseases, by mediating a diverse set of responses. 
They are essential in the host defense against various bacterial, viral and fungal 
infections, and the responses elicited by Th17 cytokines are important for controlling 
dissemination of infectious agents beyond the mucosa [126, 127]. Interestingly, IL-17 
is not only produced by Th17 cells; under certain conditions γδT cells [128, 129], CD8+ 
T cells [130] NKT cells [131] can secrete IL-17. 
 
The ability of IL-17 to mobilize neutrophils is believed to be the principal reason as to 
why this cytokine is important for protection against infectious pathogens [132]. IL-17 
induces neutrophil influx through the production of cytokines and chemokines such as 
IL-6, IL-8 and GM-CSF [133]. In addition, the Th17 cytokines IL-17 and IL-22 
cooperatively enhance expression of AMPs associated with host defense [134, 135] 
(Figure 4). 
 
 
 
 
 
 
 
Lu et al. demonstrated a critical role for IL-17 in mediating acquired immunity to 
pneumococci in a murine colonization model [136]. The same investigators also 
showed that IL-17 increases pneumococcal killing by human neutrophils, although the 
Figure 4. Role of Th17 cells in the mucosa. Uptake and presentation of mucosal microorganisms by 
DCs promote Th17 cell production of IL-17 and IL-22. These cytokines induce AMPs and 
neutrophil-recruiting chemokines by epithelial cells. © M. Olliver 
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precise mechanism involved was not identified. Th17 responses appear to be critical for 
immunity against colonizing pneumococci, as depletion of IL-17 or CD4
+
 T cells 
blocked the recruitment of monocytes/macrophages and neutrophils, and diminished 
pneumococcal clearance [137]. In contrast, Th17 cells were not required in the rapidly 
invasive model of pneumonia described by Cohen et al. [138]. 
 
Despite recent advances, little is known about how pneumococci generate Th cell 
responses in the human host. In one recent study, Mureithi et al. characterized T cell 
memory responses to pneumococci in healthy adults in an area of high pneumococcal 
carriage and disease. They found that pneumococci triggered both Th1 (IFN-γ) and 
Th17 (IL-17) cytokine responses in peripheral blood mononuclear cells (PBMCs), but 
that the level of T cell memory was not associated with interruption of pneumococcal 
carriage [139]. Further studies of Th cell responses in humans are needed to 
characterize T cell pneumococcal immunity acquired through asymptomatic carriage. 
 
 
1.2.3 Immunomodulatory Effects of Vitamin D 
 
The classic function of vitamin D is to enhance intestinal absorption of calcium by 
regulating calcium transport proteins in the small intestine. In the absence of vitamin D, 
dietary calcium is not properly absorbed, resulting in hypocalcemia which can cause 
rickets (softening of bones) in children and adolescents. However, the importance of 
vitamin D in the regulation of cells of the immune system has gained increased 
appreciation over the past decade.  
 
Humans obtain vitamin D precursors by exposure of their skin to the ultraviolet B 
(UVB) component of sunlight, and from diet, but to a much smaller extent. Activation 
of vitamin D requires two sequential hydroxylation steps. In the first step (in the liver) 
the enzyme 25-hydroxylase converts vitamin D to the inactive, circulating, form 
25(OH)D3. In the second step (in the kidney, as well as other tissues), 25(OH)D3 is 
activated by the enzyme 1-alpha hydroxylase (Cyp27B1), yielding the active form of 
vitamin D; 1,25-(OH)2D3.  
 
Responsiveness to vitamin D depends on expression of the nuclear vitamin D receptor 
(VDR) which binds to specific vitamin D response elements in the promoters of 
approximately 200 target genes in the human genome [140]. Nearly every tissue in the 
body has receptors for the active form of vitamin D. As reviewed by Di Rosa et al. 
[141], all immune cells express the VDR, including DCs and activated T cells [142-
144]. Potent immunomodulatory activities of vitamin D on both innate and adaptive 
immune responses have recently been discovered (Table 4). Many studies suggest that 
vitamin D can enhance innate immunity while dampening overly zealous adaptive 
immune responses; hence, it appears to play an important role in maintaining immune 
homeostasis. 
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The anti-inflammatory role of vitamin D has been documented in various bacterial 
infections [145]. Based on results by Yim et al., [146] it has been speculated that the 
use of inhaled vitamin D could augment the expression of cathelicidin on the mucosal 
surface of bronchial epithelia, thereby increasing the antibacterial activity against 
airway pathogens in patients with cystic fibrosis. 
 
Vitamin D deficiency is now recognized as a pandemic and it has been speculated 
that the alarming prevalence of vitamin D deficiency may be contributing to immune-
mediated diseases. Very few foods naturally contain vitamin D, so sun exposure is the 
major source of vitamin D. As early as in the 1920s, sun exposure was recognized as 
an effective treatment for pulmonary tuberculosis but with the advent of antibiotics 
after the First World War, the idea that regular sun exposure could protect against 
infection was forgotten.  
 
Table 4. Effects of vitamin D on the immune system 
Cell type Effect Reference 
Monocytes/ 
Macrophages 
Induces autophagy via cathelicidin to facilitate 
destruction of Mycobacterium tuberculosis within 
auto-phagolysosomes 
[147] 
Monocytes/ 
Macrophages 
Triggers antimicrobial activity 
 
[148] 
Monocytes 
 
Inhibits differentiation into DCs in vitro 
 
[149] 
Bronchial 
epithelial cells 
Increases antibacterial activity against airway 
pathogens by stimulating induction of cathelicidin 
[146] 
Monocyte-derived 
DCs 
Increases IL-1β and IL-6 production and inhibits 
antigen presentation 
[150] 
CD4
+
 T cells Inhibits production of IFN-γ and IL-17  [151] 
T cells Induces regulatory T cell responses [152] 
Macrophages and 
epithelial cells 
Induces AMPs 
 
[153] 
 
Due to the immunoregulatory and immunosuppressive roles of vitamin D, there has 
been increasing clinical interest for applications of vitamin D in immune-related 
disorders. Animal models with vitamin D have shown promising results in 
autoimmune diseases such as type 1 diabetes [154] and arthritis [155]. 
 
Martineau and colleagues undertook a randomized controlled trial of vitamin D in 
adults with pulmonary tuberculosis in 2011. They assessed the potential of 10 mg 
supplemental vitamin D to accelerate rates of sputum culture conversion, and found 
that a small subset of patients with the tt Taql VDR genotype had enhanced sputum 
culture conversion rates with vitamin D [156]. Thus, inherited factors may influence 
responses to vitamin D supplementation. In a similar study by Wejse et al., 
supplementary vitamin D did not improve clinical outcome and had no overall effect 
on mortality in tuberculosis patients [157]. However, in this study, the 
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supplementation group did not show increased serum 25(OH)D3 levels when 
compared with the placebo group, which makes it difficult to interpret the data. 
In another recent clinical trial, Urushima et al. investigated the effect of vitamin D 
supplements during winter on the incidence of seasonal influenza A in 
schoolchildren. In this study, influenza A occurred in 10.8% of children in the 
vitamin D group compared with 18.6% in the placebo group, suggesting that vitamin 
D supplementation may reduce the incidence of influenza A [158]. 
 
Although the precise immunomodulatory mechanisms of vitamin D are still being 
discovered, vitamin D supplementation may hold therapeutic promise in many 
diseases characterized by inflammation, including malignancies, cardiovascular 
diseases, autoimmune disorders and infections. Previous to the work described in this 
thesis, the impact of vitamin D on immune responses to the pneumococcus was 
unknown. However, in paper III, we speculate that vitamin D might be useful as an 
immunomodulatory drug, targeting the inflammatory response in pneumococcal 
disease. 
 
 
1.2.4 Primary Immunodeficiencies  
 
Primary immunodeficiencies (PIDs) are genetic disorders in which part of the immune 
system is missing or does not function properly. Most PIDs are diagnosed in young 
children, although milder forms may not be recognized until adulthood. Currently, 
more than 150 PIDs are recognized [159], and these can be divided into subgroups 
based on the component of the immune system that is affected.  Patients with PID 
disorders are susceptible to infections that, if left untreated, may be fatal. The standard 
therapy for PIDs that include antibody deficiencies is intravenously administered 
immune globulin (IVIG). Many patients are also managed with antibiotic prophylaxis 
and some are given immunizations for encapsulated bacteria, like the pneumococcal 
conjugate vaccine. Nevertheless, many patients still experience frequent infections and 
more research is needed to elucidate the immunological abnormalities. 
 
For the purpose of this thesis, two disorders; Hyper-IgE syndrome (HIES) and common 
variable immunodeficiency (CVID), will be described. 
 
 
HIES 
 
HIES is a PID characterized by recurrent staphylococcal skin abscesses and severe 
pulmonary infections. Dominant-negative mutations in STAT3, a transcription factor 
that mediates signaling of a multitude of cytokines and growth factors, have been 
identified as a major molecular cause of HIES [160]. Since STAT3 plays a critical role 
in the signal transduction of many cytokines, it is difficult to determine which pathway 
is critical for the signs of HIES. Many reports have indicated that the production of 
Th17 cytokines, including IL-17, from HIES patients is much lower than those from 
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control individuals [160-162], suggesting that the impaired development of Th17 cells 
may account for the immunological abnormalities of HIES. However, these findings 
raise the question of why systemic Th17 cell defects lead to the unique susceptibility to 
particular infections, confined to the skin and lung, seen in HIES patients. More 
research into the molecular mechanisms underlying HIES will hopefully open up 
possibilities for exploring new approaches to treat these patients. 
 
 
CVID 
 
CVID is the most commonly encountered PID in clinical practice (for a review, see 
[163]). It represents a heterogeneous collection of disorders resulting mostly in 
antibody deficiency and recurrent infections. The low levels of antibodies (IgG, IgA 
and/or IgM) render patients susceptible to common bacterial and viral infections. In 
addition, patients respond poorly to vaccinations with protein and polysaccharide 
antigens such as the pneumococcal vaccine. Approximately 50% of patients with CVID 
also have T cell dysfunction. In recent years, significant progress has been made in 
elucidating genetic mechanisms that can result in a CVID phenotype; however, there 
still remains significant work to be done in improving our understanding of the disease.  
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1.3 BACTERIA HOST INTERACTIONS 
 
S. pneumoniae is a fascinating bacterium from an immunological point of view. As a 
commensal of the human respiratory tract, it normally colonizes individuals without 
causing any symptoms. However, when it transmigrates into the lungs, enters the blood 
stream or crosses the blood-brain barrier, it transforms from a harmless colonizer to a 
serious pathogen able to cause life-threatening diseases. The host immune response to 
pneumococci must be balanced in order to induce sufficient clearance of bacteria 
while at the same time limit tissue damage. Nevertheless, the pneumococcus has a 
range of factors that enable it to evade immune defenses and cause disease. 
 
 
1.3.1 Pneumococcal Components 
 
A large number of pneumococcal factors related to host interactions have been 
described. These components are often called virulence factors. However, there are 
limitations to the concept of virulence, which assumes that bacteria are equipped with 
factors to harm the host. It is difficult to define virulence factors in the absence of host 
factors and the host response [164], and hence, the concept of virulence works for some 
bacterial pathogens but may be less suited for commensal bacteria with pathogenic 
potential, like the pneumococcus.  
 
 
Polysaccharide Capsule 
 
Pneumococci are encased by a capsular polysaccharide and the capsule is recognized as 
a sine qua non for invasive diseases. It is possible that host recognition of highly 
conserved motifs on the bacterial surface has pushed microorganisms to surround 
themselves with capsules, which can hide their underlying sensitive structures from 
host detection. The capsule protects pneumococci from phagocytosis by immune cells 
and is essential for survival in the blood. On the other hand, expression of the capsule 
can be downregulated during colonization of epithelial cells [165]. This may be 
beneficial for the bacterium since lower amounts of capsule enhances adherence and 
may promote colonization. 
 
 
Cell Wall 
 
The cell wall of pneumococci is built up by several layers of peptidoglycan and is rich 
in teichoic acids (TA) and lipoteichoic acid (LTA). Another important feature of the 
pneumococcal cell wall is choline, to which many pneumococcal proteins are anchored 
(Figure 5).  
 
Peptidoglycan is constituted of glycan chains made of N-acetylglucosamine and N-
acetylmuramic acid disaccharide subunits which are linked to peptide stems. 
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Peptidoglycan induces immune activation, and originally it was thought to signal via 
TLR2 [166, 167]. However, more recently, it has been shown that small quantities of 
LTA are present in commercial peptidoglycan preparations and that if the preparations 
are repurified to eliminate LTA, the TLR2-dependent activity of peptidoglycan is 
abolished [168]. 
 
 
 
 
 
Muropeptides are breakdown products of peptidoglycan which are released during 
bacterial growth and division. They are also released after phagocytosis as part of the 
host response, triggering intracellular signaling cascades and activation of the immune 
response.  
 
Muramyl dipeptide (MDP) is a prominent muropeptide, known since the 1970s to be 
the minimal structure that displays adjuvant activity [169]. It is recognized by the 
cytoplasmic receptor NOD2 [110]. Some authors have found that MDP induces 
cytokine release from immune cells [170] whereas others have reported that it does not 
[171]. Possible explanations for the different results could be different origin and purity 
of the muropeptides, contamination by LPS, or the unphysiologically high 
concentrations of MDP used [172]. Notably, Iyer and Coggeshall recently showed that 
intact polymeric peptidoglycan is a better stimulator of human innate immune cells than 
peptidoglycan monomers such as MDP, and that the polymeric nature of peptidoglycan 
is required for efficient phagocytosis and lysosomal degradation [173]. 
 
 
Surface Proteins 
 
Pneumococci possess more than 500 surface proteins. Three main groups have been 
identified: lipoproteins, LPXTG-proteins, and choline-binding proteins (CBPs). These 
Figure 5. The pneumococcal cell wall. The pneumococcal cell wall consists of peptidoglycan, 
teichoic acid, lipoteichoic acid, choline and choline-binding proteins. © M. Olliver 
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proteins enable the bacterium to colonize and adhere to the nasopharyngeal and 
respiratory tract epithelium. They are also involved in bacterial fitness, cell-cell contact, 
elimination of competitors and host interaction. During the various stages of the 
infection, when pneumococci have to adapt to different niches, expression of these 
proteins occurs in a highly regulated manner [174]. 
 
 
Pneumolysin 
 
Pneumolysin, a 53 kDa protein that is present in virtually all clinical isolates of S. 
pneumoniae, is one of the most widely studied pneumococcal factors. At high doses, 
the toxin binds to and creates large pores in cholesterol-containing host cell 
membranes [175], causing host cell lysis and death [86, 176]. At low doses, 
recombinant pneumolysin has been shown to activate the complement system [177], 
inhibit chemotaxis of neutrophils [178], and induce cytokine production from human 
monocytes and neutrophils [179, 180]. Recombinant pneumolysin was also shown to 
cause damage to human ciliated epithelium in vitro [181]. 
  
It has previously been believed that pneumolysin is an intracellular protein that is 
only released when cells undergo autolysis [182], but a more recent report showed 
that pneumolysin is primarily localized to the cell wall compartment during growth in 
the absence of detectable cell lysis [183]. 
 
The role of pneumolysin in the pathogenesis of infection has been widely studied in 
animal models. Mice infected with a pneumolysin-deficient strain showed reduced 
lethality and diminished inflammatory responses in the lungs when compared to wild 
type [182, 184-186]. In otitis media and meningitis models, however, others have 
reported that pneumolysin does not have an effect on inflammation [187, 188]. 
Furthermore, clinical isolates expressing non-hemolytic forms of pneumolysin have 
been detected in IPD patients [189, 190], demonstrating that the hemolytic activity of 
the toxin is not essential for invasive disease. In addition, there has also been a report of 
a clinical isolate with no pneumolysin expression [191]. Hence, although many animal 
studies have established pneumolysin as an important virulence factor, the picture is not 
clear.  
 
While murine models have been invaluable for studying pneumococcal pathogenesis, 
care should always be taken in extrapolating the results from murine cells to the human 
response. In addition, studying the effects of isolated recombinant pneumolysin may 
not give the same results as looking at the more complex interactions between whole 
bacteria and host cells. Furthermore, deletion of a single virulence factor to determine 
the contribution of this factor to the overall virulence phenotype can be difficult. 
Pneumococci possess numerous attributes that contribute to virulence and tools to study 
the combination of virulence factors simultaneously are needed. 
 
 
 24 
 
1.3.2 Naturally Acquired Protection against S. pneumoniae 
 
Both the prevalence of pneumococcal colonization and the incidence of 
pneumococcal disease in unvaccinated children decline over the course of childhood 
[6, 192, 193]. The reason for the changing susceptibility to pneumococcal carriage 
and disease after the first years of life is not fully understood. Potential mechanisms 
that underlie naturally acquired protection against pneumococci will be described 
here. 
 
Age-related maturation of the immune system 
Age-related changes in susceptibility to infections may be due to maturation of the 
immune system. Bogaert et al. showed that similar to what is observed in humans, the 
clearance of pneumococcal colonization in infant mice is significantly impaired 
compared to that in adult mice [50]. In the human system, differences in TLR-
mediated cytokine responses in cells from infants compared to adults have been 
reported [194, 195]. These studies indicate that when the immune response matures 
with age, it becomes increasingly capable of mounting innate and adaptive responses 
to pneumococci. 
 
Humoral immunity by antibody directed against the capsule 
It has generally been thought that the immune response to pneumococci in naturally 
exposed, unvaccinated children depends primarily on antibodies directed against the 
polysaccharide capsule. The reason for this is that immunization with the 
polysaccharide and conjugate vaccines generate effective serotype-specific antibody 
responses [196, 197]. In addition, patients with antibody deficiencies are at increased 
risk of pneumococcal disease [198]. Immunity by serotype-specific opsonic 
antibodies is thought to mediate protection by enhancing the bactericidal effect of 
host phagocytes. 
 
Relatively few data exist on immune responses to the pneumococcus after natural 
exposure. Some of these studies have presented evidence for serotype-specific acquired 
immunity. Weinberger et al. analyzed longitudinal carriage data from Israeli toddlers 
attending day care, and observed a serotype-specific acquired immunity to 
pneumococcal carriage in some of the serotypes investigated [199]. There was a lower 
risk of colonization with serotypes 6A, 14 and 23F after previous exposure to the 
homologous type. They found no evidence of specific protection for serotypes 6B, 15 
and 19F. However, this type of observational study has some limitations. For example, 
when subjects were sampled, the serotype of only one colony was determined and since 
multiple serotypes can potentially colonize the same individual, the dominant type 
would most likely be the one that is detected. Another study, in adults, showed that 
levels of anticapsular antibodies increase significantly after carriage of some, though 
not all, serotypes [6]. 
 
However, lately the assumption that anticapsular antibodies are the primary mechanism 
of naturally acquired immunity to pneumococci has been questioned. The timing of 
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protection appears before anticapsular antibody responses can be detected in most 
children, and there is a simultaneous decline in carriage and disease for many 
serotypes, which would be unlikely if separate antibody responses were required for 
protection against each serotype [192]. In addition, in an experimental challenge study 
in adults there was no evidence of an association between prechallenge anticapsular 
antibody concentration and protection [200]. Furthermore, Granat et al. found that 
previous pneumococcal carriage was associated with a serotype-independent protection 
from subsequent acquisition in Bangladeshi children [201], consisted with the 
hypothesis that serotype-independent immunity is stimulated in young children by 
previous pneumococcal carriage. Finally, McCool and Weiser reported that clearance 
of pneumococcal carriage in mice could occur independently of antibody [202], 
suggesting that other components of the immune response may play a role. 
 
Antibody-independent T cell-dependent cellular immunity  
In 2004, Kadiouglu et al. showed that mice with a deletion of the MHC-II gene, 
which are effectively CD4-T-cell negative, are significantly more susceptible to 
pneumococcal bronchopneumonia and septicemia than their isogenic wild-type 
parents [203]. Since then, a number of papers have reported observations relevant to 
the role of CD4
+
 T cells in the host immune response to pneumococcal infection [103, 
136, 204, 205]. 
 
The Th17 cell response to pneumococci is increasingly recognized as an important 
mediator of immunity and several mouse studies have shown the importance of these 
responses in inducing neutrophil and monocyte/macrophage mediated clearance of 
colonizing bacteria [136, 137]. IL-17-mediated immunity to pneumococcal 
colonization was also observed in mice immunized intranasally with the 
pneumococcal cell wall polysaccharide [206]. However, in a recent study by Cohen et 
al., protection against invasive pneumococcal infection in mice was due to serum 
antibody responses (that promoted clearance of pneumococci from the blood) and not 
a CD4-dependent IL-17 response [138], suggesting that the protective Th17-mediated 
effects of nasopharyngeal colonization may depend on the site of subsequent 
challenge. 
 
There are contradictory reports on the role of the Th1 cytokine IFN-γ in protection 
against pneumococcal infection in murine models [207, 208] . Nevertheless, Kemp et 
al. found that IFN-γ producing T cells disappear from the circulation in patients with 
pneumococcal pneumonia, suggesting that these cells are engaged in the immune 
response [209]. 
 
Few studies have explored human CD4
+
 T cell responses to pneumococci. Mureithi et 
al. showed that following challenge with pneumococcal antigens, human PBMCs 
produce IL-17 and IFN-γ in vitro [139]. Recently, Pido-Lopez et al. demonstrated an 
age-related sequestration of Th1 and Th17 CD4
+
 T cells reactive to pneumococcal 
protein antigens within mucosal lymphoid tissue [210]. Their experiments also 
revealed the presence of antigen-specific regulatory T cells, suggesting that the 
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balance between mucosal effector and regulatory Th cell immunity is critical to 
pneumococcal commensalism. 
 
A better understanding of the mechanisms by which pneumococci trigger human Th 
cell responses may facilitate the design of new pneumococcal vaccines based on cell-
mediated immunity. 
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2 AIMS 
 
The overall aim of this thesis was to explore the complex interactions between S. 
pneumoniae and its human host. Focus has been on human dendritic cells (DCs) and 
the innate and adaptive immune responses they induce after infection with live 
pneumococci. An improved understanding of host defense mechanisms against 
pneumococci might lead the way for the development of novel therapeutic strategies to 
regulate immune responses and inflammation. 
 
The specific aims of the papers were: 
 
 To study the response of human DCs to a live pneumococcal infection and 
investigate the effect of the pneumococcal cytotoxin pneumolysin on DC 
viability, maturation and production of inflammatory cytokines. Furthermore, to 
compare the responses of human and murine DCs. (Paper I) 
 
 To investigate the role of monocytes in promoting Th responses to live and 
heat-killed pneumococci. Also, to identify pneumococcal components 
responsible for triggering production of Th1 and Th17 effector cytokines. 
(Paper II) 
 
 To further explore the interactions of pneumococci and DCs, as well as 
mechanisms underlying pneumococcus-induced Th responses. In addition, the 
objective was to examine the immunological effects of vitamin D on immune 
functions in response to pneumococci. (Paper III) 
 
 To determine whether patients with PIDs exhibit impaired production of AMPs 
and whether this could be linked to an aberrant Th17 response. (Paper IV) 
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3 METHODOLOGICAL AND ETHICAL 
CONSIDERATIONS 
 
This chapter contains information about the bacterial strains and cells used in papers I-
IV. For more details about the in vitro infection assays, see the Materials and Methods 
sections of the respective papers. 
 
 
3.1 BACTERIA 
 
Throughout this work, the serotype 4 strain T4 (TIGR4, ATCC BAA-334) and its non-
encapsulated mutant T4R were used. The strain T4 was originally isolated from the 
blood of a Norwegian patient and its genome was sequenced in 2001 [211]. T4 is 
commonly used in laboratories around the world and shows a high level of virulence in 
mice [106]. 
 
Virtually all clinical isolates of S. pneumoniae contain an external capsule. However, in 
our initial in vitro infection assays with human DCs, using serotype 4 pneumococci, we 
found that only the unencapsulated strain T4R was readily taken up by the cells. 
Significant uptake of the encapsulated parent strain T4 was only observed under 
opsonized conditions, high infection doses or long infection times. For this reason we 
used T4R in many of the experiments. The rationale for this was that we anticipated 
that the results observed with unencapsulated T4R in our studies would reflect the 
physiological (in vivo) conditions with opsonised uptake of encapsulated pneumococci. 
 
In paper I, II and III, T4 and T4R mutants lacking pneumolysin were used. These 
mutants were created by insertion-deletion mutagenesis, and the targeted gene was 
replaced by an erythromycin-resistance cassette. 
 
In paper I, a number of clinical isolates of serotype 1 were used. These belong to the 
sequence type (ST) 306, producing a non-hemolytic form pneumolysin, as well as 
ST228, ST217 and ST227, producing hemolytic pneumolysin. All clinical isolates were 
obtained from Birgitta Henriques-Normark at the Swedish Institute for Infectious 
Disease Control, Department of Bacteriology. In paper II, clinical isolates of serotype 
9 and 14 were also used, as well as the serotype 2 strain D39 (obtained from Peter 
Hermans, Rotterdam, The Netherlands). 
 
Pneumococci were grown over night on blood agar plates at 37˚C in 5% CO2. Colonies 
were grown in C+Y medium (Karolinska University Laboratories) to mid-log phase, 
then pelleted by centrifugation and diluted with cell culture medium prior to infection 
of cells. In some experiments, bacteria were heat-killed by incubation of cultures for 20 
minutes at 90˚C. Killing was confirmed by plating bacteria on blood agar plates.  
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3.2 CELLS 
 
The majority of experiments included in the papers of this thesis were performed with 
primary immune cells, isolated from the blood of human donors. 
 
For paper IV, ethical approval for blood collection from patients and healthy controls 
was obtained from the research ethical committee at Karolinska Institutet, and written 
informed consent was obtained from all patients prior to inclusion and sample 
collection. Approval for the generation of murine DCs, for paper I, was obtained from 
the ethical committee on animal research of Stockholm, section north. 
 
Monocyte-derived DCs 
In paper I and III, monocyte-derived DCs were used. Buffy coats were obtained from 
healthy volunteers, provided by Karolinska University Hospital. PBMCs were isolated 
by density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare) and 
monocytes were obtained either by negative selection with RosetteSep human 
monocyte enrichment cocktail (StemCell Technologies) (paper I), or by incubation of 
PBMCs to a large plastic culture flask where monocytes were allowed to adhere for 
two hours (paper III). Monocytes were then cultured for 6 days in cell culture medium 
in the presence of GM-CSF and IL-4. The DC phenotype was assessed for surface 
marker expression (CD14
-
, CD11c
+
 and CD1a
+
) with fluorescently labeled antibodies. 
 
Murine bone marrow-derived DCs 
In paper I, we used murine bone marrow-derived DCs, to compare some of the 
responses to human DCs. Primary cells were obtained from the bone marrow of 6-10 
week old C57BL/6 and BALB/c mice and the cells were differentiated for 6 days in the 
presence of recombinant murine GM-CSF. The phenotype of the cells was assessed by 
examining the expression of CD11c.  
 
Murine cells are commonly used in pneumococcal infection studies. However, as mice 
are not natural hosts for pneumococci, receptor expression and cellular composition in 
these cells may differ from human cells, and care must be taken to directly extrapolate 
the results from murine cells to the human response. 
 
Monocytes 
Monocytes were used in paper II. Buffy coats were obtained from healthy 
volunteers, provided by Karolinska University Hospital. PBMCs were isolated by 
density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare) and 
monocytes were purified by negative selection with RosetteSep human monocyte 
enrichment cocktail (StemCell Technologies). Monocyte purity was assessed by 
examining CD14 expression. 
 
CD4
+
 T cells 
In paper II and III, CD4
+
 T cells were used in co-cultures with monocytes or DCs. 
Unfractionated CD4
+
 T cells were purified from buffy coats by negative selection with 
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RosetteSep human CD4
+
 T cell enrichment cocktail (StemCell Technologies), and 
memory and naïve CD4
+
 T cells were prepared with EasySep human memory CD4
+
 T 
cell enrichment kit and EasySep human naïve CD4
+
 T cell enrichment kit (StemCell 
Technologies), respectively. The purity of the cells was assessed by examining 
expression of CD3, CD4 (unfractionated CD4
+
 T cells) as well as CD45RO (memory 
CD4
+
 T cells) and CD45RA (naïve CD4
+
 T cells) with fluorescently labeled antibodies. 
 
PBMCs 
In paper IV, PBMCs were isolated from whole blood of patients and healthy controls 
by density gradient centrifugation (Lymphoprep). The PBMCs were cryopreserved and 
on the day of the experiment, cells were quickly thawed in a 37˚C water bath, washed 
twice and resuspended in cell culture medium. 
 
Detroit 562 (D562) nasopharyngeal epithelial cells 
In paper III, a human pharynx carcinoma cell line, called D562, was used for analysis 
of IL-8 mRNA expression. The advantage of using a cell line is that it is possible to 
perform several experiments with cells of the same origin. However, immortalized cells 
may express different receptors from primary cells which creates concerns about the 
biological relevance. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
“Streptococcus pneumoniae Evades Human Dendritic Cell Surveillance by 
Pneumolysin Expression” 
 
In paper I, published in 2009, we investigated the dynamics of human DC interaction 
with live pneumococci, with a focus on the pneumococcal cytotoxin pneumolysin. 
Using in vitro infection assays, we examined uptake and intracellular processing of 
pneumococcal strains by the DCs with gentamicin-protection assays and transmission 
electron microscopy (TEM). We also examined DC viability and functions such as 
expression of maturation markers and cytokines, using flow cytometry and ELISA 
analyses. In addition, we compared some of the human DC responses to those of 
murine DCs. 
 
Our assays revealed that unencapsulated pneumococci are readily taken up by DCs. 
Significant uptake of the encapsulated parent strain was only observed under opsonized 
conditions, high infection doses or long infection times. We found that uptake of a 
pneumolysin-deficient mutant was lower than for the pneumolysin-producing parent 
strain, suggesting that bacteria-bound pneumolysin interacts directly with host cell 
receptors. However, the specific receptors and mechanisms involved need to be further 
examined.  
 
In addition, we showed that production of pneumolysin affects intracellular processing 
of pneumococci by the DCs. At 4 hours p.i., the majority of pneumolysin-producing 
bacteria appeared in tight vacuoles, whereas pneumolysin-deficient bacteria were found 
in both spacious and tight vacuoles (Figure 6). Nevertheless, at 8 hours p.i., both 
pneumococcal strains were localized in tight vacuoles. These results indicate that 
pneumolysin may be involved in the transition of bacteria from spacious to tight 
vacuole. It appears that bacteria inside tight vacuoles in fact reside free in the 
cytoplasm; however, further characterization of these compartments is required to 
examine the degree of contact between bacteria and the cytosol. 
 
      
 
Infection with pneumolysin-producing pneumococci activated multiple caspases and 
induced significant apoptosis of the infected DCs. The apoptotic effect of pneumolysin 
Figure 6. Pneumococci 
reside in two types of 
vacuoles following uptake. 
Left: Pneumolysin-producing 
pneumococcus in a tight 
vacuole in close contact with 
the cytosol. Right: 
Pneumolysin-deficient 
pneumococci in spacious and 
tight vacuoles. TEM pictures 
by Kjell Hultenby. 
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was more pronounced in the unencapsulated background, suggesting that it is 
dependent on an intracellular location. Unexpectedly, we found that pneumolysin 
diminished activation of the DCs. Infection with pneumolysin-producing pneumococci 
resulted in significantly lower expression of the surface activation markers CD80 and 
CD86 in live DCs compared to the pneumolysin-deficient mutant.  
 
Several investigators have reported that exposure of human immune cells to 
recombinant pneumolysin induces inflammatory cytokines [179, 180]. However, in our 
experiments with human DCs, using intact bacteria, we found that pneumolysin-
deficient pneumococci induce significantly higher levels of the inflammatory cytokines 
IL-12p70, IL-8 and IL-1β compared to wild type. Interestingly, the 30-fold increased 
amount of IL-12p70 induced by the pneumolysin-deficient strain could not be solely 
attributed to higher cell viability, which was only 3-fold. Instead, we speculate that an 
increased early signaling to vacuolar receptors leads to the enhanced inflammatory 
response, since pneumolysin-deficient bacteria were located within spacious vacuoles 
for an extended period after infection. 
 
In addition to the serotype 4 pneumolysin knock-out mutant, we also performed 
experiments with clinical isolates of serotype 1, expressing non-hemolytic forms of 
pneumolysin [190]. Pathogenic serotype 1 isolates producing non-hemolytic 
pneumolysin are frequently isolated from sterile sources [189], demonstrating that the 
hemolytic activity of the toxin is not essential for invasive disease. Similar to the 
serotype 4 pneumolysin-deficient mutant, these strains were more proinflammatory and 
caused less apoptosis than clonally related strains expressing hemolytic pneumolysin. 
 
Most studies examining the impact of pneumolysin have been performed with murine 
cells. Our results are in contrast to the previously reported proinflammatory nature of 
pneumolysin in murine macrophages [212]. Therefore, we wanted to compare the 
cytokine response to pneumococci between human and murine DCs following infection 
with pneumolysin +/- strains. Interestingly, the production of IL-12p70 followed the 
same pattern in human and murine DCs, whereas in murine cells IL-1β was only 
induced following infection with pneumolysin-producing bacteria. Thus, we could 
repeat what has previously been reported, namely that pneumolysin can stimulate a 
proinflammatory response. Importantly, these results highlight the need to study human 
responses to this human-specific pathogen. 
 
To conclude, this paper shows that the pneumococcus possesses the capacity to evade 
human DC-mediated immune responses. Firstly, expression of the capsule inhibits 
internalization, thus reducing intracellular sensing of pneumococcal ligands. Secondly, 
pneumolysin inhibits DC-mediated immunosurveillance such as cytokine production 
and co-stimulation of T cells. Thirdly, the observed induction of apoptosis by 
pneumolysin-producing strains may compromise the development of DC-mediated 
adaptive immune responses against pneumococci. Taken together, modulation of DC-
induced immunity may be a strategy by which the pneumococcus promotes 
colonization and disease. 
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4.2 PAPER II 
“Human Monocytes Promote Th1 and Th17 Responses to Streptococcus 
pneumoniae” 
 
Natural immunity to pneumococcal infections has been assumed to depend on 
anticapsular antibodies. However, recent findings from murine models suggest that 
alternative mechanisms, which are dependent on Th cells, are also involved [202, 
204, 205]. Since the immunological events in which Th cells contribute to immunity 
have mainly been studied in mice, we wanted to examine how these responses are 
generated in the human system. Consequently, in paper II, published in 2011, we 
investigated bacterial and host factors involved in the induction of Th1 and Th17 
responses, using a co-culture model of human monocytes and CD4
+
 T cells. 
 
We could show that pneumococcus-infected monocytes promote effector cytokine 
production by memory Th cells, leading to a mixed Th1/Th17 (IFN-γ/IL-17) 
response. Interestingly, we found that live and heat-killed pneumococci induced 
distinct cytokine responses and that different mechanisms were involved in the 
promotion of Th1 and Th17 cytokines. Accordingly, live bacteria triggered a Th1-
biased response that was a 100-fold higher than that to heat-killed bacteria. IFN-γ 
production was dependent on monocyte production of IL-12 and was enhanced in the 
absence of the pneumococcal capsule and the presence of human serum. Furthermore, 
we found that live bacteria were phagocytosed 20-fold more than heat-killed bacteria. 
Taken together, these results suggest that the Th1 dominant response is induced by 
the presence of internalized viable pneumococci.  
 
Heat-killed bacteria triggered Th17 cytokine production through TLR2 signaling; 
however, our results showed that this receptor is not involved in the Th response to 
live bacteria. It has previously been shown that internalized pneumococci trigger 
activation of NOD2 [111, 112], though it remains to be elucidated if NOD2 is 
involved in the promotion of Th cytokines in response to live pneumococci in our 
system. 
 
Live pneumococci triggered a dose-dependent increase in IFN-γ, but not IL-17, and we 
asked ourselves if this was because live bacteria could induce Th1-skewing conditions 
that prevent the induction of a Th17 response. To test this hypothesis, we added 
exogenous recombinant IL-12p70 to cocultures infected with heat-killed bacteria, 
known to trigger substantial levels of IL-17. This led to a significant decrease in IL-17, 
suggesting that IL-12 has an important role in establishing the Th1/Th17 balance. A 
negative relationship between Th1 and Th17 cytokines has previously been reported 
[213, 214].  
 
In an effort to elucidate which pneumococcal factors were responsible for the Th 
cytokine response, we examined the influence of various pneumococcal components. In 
contrast to a previous study by McNeela et al. [215], we found no difference in the 
induction of IFN-γ and IL-17 between wild type pneumococci and a pneumolysin-
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deficient mutant. Capsular type and the capsule itself did not appear to be important. 
Rather, our results suggested that pneumococcal peptidoglycan is a potent trigger of 
both Th1 and Th17 cytokines. 
 
To summarize, this work provides evidence that pneumococcal peptidoglycan triggers 
the production of Th1 and Th17 cytokines from human memory cells, and that the 
balance between the two immune effector arms depends on bacterial viability. An 
increased understanding of human Th responses is essential for the development of 
pneumococcal vaccines designed to elicit cell-mediated immunity. A deeper 
understanding of the pathways that regulate Th cytokines may also be used to develop 
immunomodulatory therapies to suppress excessive mucosal inflammation in 
pneumococcal infections. 
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4.3 PAPER III 
“Human dendritic cells, activated by pneumococcal peptidoglycan, promote 
innate and adaptive immune responses which can be modulated by vitamin D” 
 
DCs play a central role in regulating innate and adaptive immune responses against 
commensal and pathogenic bacteria. However, little is known about what drives DC-
mediated immune responses to pneumococci in humans. Paper III, a manuscript, aims 
at examining the ability of human DCs to induce innate and adaptive immune responses to 
the pneumococcus. In addition, we investigated the immunomodulatory effects of vitamin 
D on DC-mediated immune functions. 
 
We showed that uptake of live pneumococci and pneumococcus-derived purified 
peptidoglycan induce DC maturation and cytokine production. Supernatants from 
stimulated DCs induced an inflammatory IL-8 response in nasopharyngeal epithelial cells, 
measured as an increase in mRNA levels. DCs co-cultured with CD4+ T cells promoted 
Th1 and Th17 memory cytokines (IFN-γ and IL-17), in a cytokine and contact-dependent 
manner. These results suggest a role for Th1 and Th17 cells in establishing anti-
pneumococcal immunity.  
 
Vitamin D is a well-known immunomodulator [149, 151]; however, nothing is known 
about the impact of vitamin D on pneumococcal immune responses. In our experiments, we 
found that addition of vitamin D enhanced maturation of DCs and skewed the Th response 
from an inflammatory Th1/Th17 phenotype towards a regulatory T cell phenotype. These 
data indicate that vitamin D regulates the immune balance in response to pneumococci by 
mitigating inflammation caused by the adaptive immune response. Although local 
inflammatory responses may be beneficial by preventing the pneumococcus from invading 
mucosal tissues and cause disease, excessive inflammation may result in tissue damage. 
Our findings suggest that vitamin D might be useful as an immunomodulatory drug, 
targeting pneumococcus-induced inflammation.  
 
To conclude, our results demonstrate that memory CD4+ T cells responding to S. 
pneumoniae stimulation can be detected in the circulation of healthy donors, and that 
pneumococcal peptidoglycan is a potent trigger of DC-mediated immune responses. An 
improved understanding of the interactions between human host cells and pneumococci 
may lead to development of novel therapeutic strategies, including regulation of immune 
responses and inflammation.  
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4.4 PAPER IV 
“Impaired Release of Antimicrobial Peptides into Nasal Fluid of Hyper-IgE and 
CVID Patients” 
 
Patients with PIDs often suffer from frequent respiratory tract infections, despite 
standard treatment with IVIG and antibiotics. In paper IV, published in 2011, we 
sought to investigate if additional immunological abnormalities are present among 
patients with various PID diagnoses. Two key components of the innate and adaptive 
immune system were examined, namely induction of AMPs (LL-37 and HNP1-3) and 
Th17 cells (IL-17).  
 
We collected nasal fluid, nasopharyngeal swabs and PBMCs from patients as well as 
healthy controls. AMP levels were measured in nasal fluid and nasal swabs were 
cultured for bacteria. PBMCs were stimulated with antigen and the supernatant was 
assessed for IL-17 release. 
 
We could show that healthy controls and most patients colonized with a primary 
pathogen, such as S. pneumoniae, exhibited increased levels of AMPs in nasal fluid 
compared to individuals with a negative bacterial culture. However, there was no 
increase in neither LL-37 nor HNP1-3 in CVID and HIES patients, despite growth of 
pathogenic bacteria. 
 
Th17 cells are instrumental in mucosal immunity by orchestrating the production of 
AMPs in epithelial cells as well as by recruiting neutrophils to mucosal tissues [216]. 
To investigate if lack of AMP expression in nasal fluid in CVID and HIES patients 
could be correlated with an impaired release of IL-17 from circulating immune cells, 
we measured IL-17 in antigen-stimulated PBMCs. Milner et al. previously showed that 
naive T cells from patients suffering from HIES cannot differentiate into Th17 cells 
[162]. In accordance with these results, we found that PBMCs from HIES patients did 
not produce IL-17 in response to antigenic stimuli. Interestingly, CVID patients also 
exhibited an impaired production of IL-17, which has not previously been reported. 
These results warrant further investigations to elucidate the mechanisms involved.  
 
Taken together, this investigation presents evidence that suggest that CVID and HIES 
patients have a dysregulated AMP response to pathogenic bacteria in the upper 
respiratory tract, which could be linked to an aberrant Th17 cell response. Our data 
also suggest that patients with certain PIDs may benefit from AMP-inducing agents 
such as vitamin D. 
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5 CONCLUDING REMARKS 
 
DCs are the most potent APCs of the immune system. They play a central role in regulating 
the nature of innate and adaptive immune responses against bacteria, both in health and 
pathology. Despite this, little is known about what drives DC responses to the 
pneumococcus in humans. In the work included in this thesis, we report that human 
DCs orchestrate a repertoire of immune responses upon sensing intracellular 
pneumococci and pneumococcus-derived peptidoglycan. Our findings provide new 
insights into mechanisms used by the pneumococcus to evade host-sensing systems, 
and call for further studies on the potential role of anti-inflammatory therapeutic 
strategies for pneumococcal diseases. 
 
Although the pneumococcus has been researched by microbiologists for over 80 years, 
we still understand relatively little about this organism as a commensal and pathogen. 
Controlling pneumococcal disease is a massive challenge that will require a 
multifaceted approach. Clinical evaluation of novel vaccine approaches (based on 
pneumococcal proteins or killed whole cells) will be of great interest, as well as 
development immunomodulatory therapies targeting the proinflammatory events 
thought to underlie the pathogenesis of invasive pneumococcal disease. 
 
Naturally acquired protection against pneumococci appears to be responsible for the 
lower rates of carriage and disease in older children and young adults. Hence, the key 
to rational strategies for control of pneumococcal disease is a better understanding of 
how natural immunity to the pneumococcus is developed. 
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